HCW Biologics Stock Surges Over 122% After Strong Earnings Report
HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session
Benzinga
Image: Benzinga
HCW Biologics Inc. (NASDAQ: HCWB) shares soared 122.55% to $0.75 in after-hours trading following a strong earnings report for Q1. The company reported earnings per share of $0.37, significantly surpassing analyst expectations and driving revenue growth due to a licensing agreement with Beijing Trimmune Biotech.
- 01HCW Biologics shares surged 122.55% to $0.75 in after-hours trading.
- 02The company reported earnings per share of $0.37, beating estimates by 184.09%.
- 03Revenue increased to $6.5 million, driven by a licensing deal with Beijing Trimmune Biotech.
- 04Net income swung to $3.5 million, recovering from a loss of $2.2 million a year earlier.
- 05The company faces going-concern doubts and has been granted a Nasdaq hearing regarding delisting.
Advertisement
In-Article Ad
HCW Biologics Inc. (NASDAQ: HCWB) experienced a remarkable 122.55% surge in its stock price, reaching $0.75 in after-hours trading on Thursday, following the release of its first-quarter earnings report. The clinical-stage biopharmaceutical company reported an earnings per share of $0.37, which far exceeded analysts' expectations of -$0.44, marking a 184.09% improvement. The revenue for the quarter was $6.5 million, a significant increase from just $5,065 in the same quarter last year, largely attributed to an exclusive licensing agreement with Beijing Trimmune Biotech for its HCW11-006 immunotherapeutic. This deal included a $3.5 million upfront license fee and a $3.5 million minority equity stake in Trimmune. Additionally, HCW Biologics reported a net income of $3.5 million, rebounding from a $2.2 million loss in the previous year. Despite these positive developments, the company has expressed concerns regarding its ability to continue operations without additional funding and is currently appealing a Nasdaq delisting determination due to non-compliance with the minimum bid price requirement. As of now, HCW Biologics has a market capitalization of $2.27 million, with a 52-week high of $10.50 and a 52-week low of $0.25.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think HCW Biologics can sustain its growth?
Connecting to poll...
Read the original article
Visit the source for the complete story.


